ClinicalTrials.gg
CompletedNCT00640822Updated Mar 7, 2025Results posted

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds

A Phase 3 interventional study of Calcipotriol plus hydrocortisone ointment vehicle and Tacalcitol Ointment in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
782
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
8th of 47
782 · median 200
Started
2008
with 4 others
Phase 3
17 of 47
none open now
Registered
13th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 8th largest by enrollment, is one of 5 that started in 2008, is one of 17 in phase 3, and was the 13th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous ares

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of psoriasis vulgaris involving the face
  • Clinical signs of psoriasis vulgaris on the trunk and/or the limbs, or earlier diagnosed with psoriasis vulgaris on the trunk and/or the limbs
  • An extent of psoriatic involvement of the face of at least 10 cm2 (the sum of all facial lesions)
  • Treatment areas (the face and the intertriginous areas) amenable to topical treatment with a maximum of 10 g of ointment per day
  • Disease severity graded as mild, moderate, severe or very severe according to the investigator's global assessment of disease severity of the face

Exclusion criteria

Exclusion Criteria:

  • Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., , vitamin D analogues, retinoids, ) within the 4-week period prior to randomisation
  • Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept, infliximab, adalimumab) within 3 months prior to randomisation
  • PUVA therapy or Grenz ray therapy within the 4-week period prior to randomisation
  • UVB therapy within the 2-week period prior to randomisation
  • Topical treatment of the face and the intertriginous areas within the 2-week period prior to randomisation (use of emollients is allowed on treatment areas during this 2-week period, but not during the study)
  • Topical treatment with very potent WHO group IV corticosteroids within the 2-week period prior to randomisation
  • Initiation of or expected changes in concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) during the study
  • Systemic treatment with vitamin D preparations above 500 IU per day
  • Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
  • Patients with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
  • Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the face or on the intertriginous areas
  • Planned exposure to sun, UVA or UVB that may affect the psoriasis vulgaris during the study
  • Known or suspected severe renal insufficiency or severe hepatic disorders
  • Known or suspected disorders of calcium metabolism associated with hypercalcemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
782 participants (actual)

Study arms

  • Experimental
    Calcipotriol plus Hydrocortisone ointment

    Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks

    Drug: Calcipotriol plus hydrocortisone ointment

  • Active comparator
    Tacalcitol

    Tacalcitol once daily for up to 8 weeks

    Drug: Tacalcitol Ointment

  • Placebo comparator
    Calcipotriol plus Hydrocortisone ointment vehicle

    Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks

    Drug: Calcipotriol plus hydrocortisone ointment vehicle

Interventions

  • DrugCalcipotriol plus hydrocortisone ointment vehicle

    Once daily application for up to 8 weeks

  • DrugTacalcitol Ointment

    Once daily application for up to 8 weeks

  • DrugCalcipotriol plus hydrocortisone ointment

    Drug pages: Calcipotriene · Hydrocortisone

    Once daily application for up to 8 weeks

06

What researchers measure

Primary outcomes

  1. Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8

    Time frame: Week 8

Secondary outcomes

  1. Overall Disease Severity of the Face According to the Investigator's Assessment

    Time frame: Week 4

  2. Total Sign Score of the Face

    Time frame: Week 8

  3. Severity Scores for Redness, Thickness and Scaliness of the Face

    Time frame: Week 8

  4. Overall Disease Severity of the Intertriginous Areas According to the Investigator's Assessment

    Time frame: Week 8

  5. Total Sign Score of the Intertriginous Areas

    Time frame: Week 8

  6. Patients With Relapse During the Study and Time to Relapse

    Time frame: Week 8-16

  7. Patients With Rebound During the Study

    Time frame: Week 8-16

07

Results

Posted Dec 21, 2010

Participant flow

Date of first subject visit was 5 Mar 2008. Date of last subject visit was 18 Jun 2009. Patients came from hospital outpatient clinics or private practice

Participant flow — Overall Study
MilestoneCalcipotriol Plus Hydrocortisone OintmentTacalcitol OintmentCalcipotriol Plus Hydrocortisone Ointment Vehicle
Started322317102
Completed27925877
Not completed435925

Outcome measures

PrimarySubjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8
Time frame:
Week 8
Reported as:
Number · Participants
Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8
ParticipantsCalcipotriol Plus Hydrocortisone OintmentTacalcitol OintmentCalcipotriol Plus Hydrocortisone Ointment Vehicle
Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 818314737
SecondaryOverall Disease Severity of the Face According to the Investigator's Assessment
Time frame:
Week 4

Results for this outcome have not been posted.

SecondaryTotal Sign Score of the Face
Time frame:
Week 8

Results for this outcome have not been posted.

SecondarySeverity Scores for Redness, Thickness and Scaliness of the Face
Time frame:
Week 8

Results for this outcome have not been posted.

SecondaryOverall Disease Severity of the Intertriginous Areas According to the Investigator's Assessment
Time frame:
Week 8

Results for this outcome have not been posted.

SecondaryTotal Sign Score of the Intertriginous Areas
Time frame:
Week 8

Results for this outcome have not been posted.

SecondaryPatients With Relapse During the Study and Time to Relapse
Time frame:
Week 8-16

Results for this outcome have not been posted.

SecondaryPatients With Rebound During the Study
Time frame:
Week 8-16

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Calcipotriol Plus Hydrocortisone Ointment—5/321 (1.6%)13/321 (4%)
Tacalcitol Ointment—3/316 (0.9%)30/316 (9.5%)
Calcipotriol Plus Hydrocortisone Ointment Vehicle—4/102 (3.9%)2/102 (2%)
Most frequent serious events
Most frequent serious events
EventCalcipotriol Plus Hydrocortisone OintmentTacalcitol OintmentCalcipotriol Plus Hydrocortisone Ointment Vehicle
Abscess limbInfections and infestations0/3210/3161/102
PregnancyPregnancy, puerperium and perinatal conditions1/3212/3161/102
DisorientationPsychiatric disorders0/3210/3161/102
ThrombosisVascular disorders0/3210/3161/102
Hip arthroplastySurgical and medical procedures0/3211/3160/102
Myocardial infarctionCardiac disorders1/3210/3160/102
Lower limb fractureInjury, poisoning and procedural complications1/3210/3160/102
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3210/3160/102
EpilepsyNervous system disorders1/3210/3160/102
Most frequent other events
Most frequent other events
EventCalcipotriol Plus Hydrocortisone OintmentTacalcitol OintmentCalcipotriol Plus Hydrocortisone Ointment Vehicle
ErythemaSkin and subcutaneous tissue disorders13/32130/3162/102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Calcipotriol Plus Hydrocortisone OintmentTacalcitol OintmentCalcipotriol Plus Hydrocortisone Ointment VehicleTotal
Mean48 ± 15.549 ± 15.548.8 ± 14.248.5 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Calcipotriol Plus Hydrocortisone OintmentTacalcitol OintmentCalcipotriol Plus Hydrocortisone Ointment VehicleTotal
Female12613641303
Male19618161438
Region of Enrollment
Region of Enrollment(participants)Calcipotriol Plus Hydrocortisone OintmentTacalcitol OintmentCalcipotriol Plus Hydrocortisone Ointment VehicleTotal
France958338216
Canada13112937297
United Kingdom9610527228
08

Study locations

3 sites
  • Probity Medical Research
    Waterloo, Ontario N2J1C4, Canada
  • Hôpital de l'Archet
    Nice, 06202, France
  • Ninewells Hospital & Medical School
    Dundee, DD1 9SY, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jun 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 21, 2008
Start
Feb 2008
Primary completionActual
Jun 2009
CompletionActual
Jul 2009
Results first posted
Dec 21, 2010
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00640822
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Mar 21, 2008
Start date
Feb 2008
Primary completion
Jun 2009
Completion
Jul 2009
Results posted
Dec 21, 2010
Last update
Mar 7, 2025

Study contacts

Colin Fleming, MD
principal investigator · Ninewells Hospital & Medical School

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Hydrocortisone

Start the discussion